IDEXX Laboratories (NASDAQ:IDXX) Stock Acquired Rep. April McClain Delaney

Representative April McClain Delaney (D-Maryland) recently bought shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX). In a filing disclosed on May 02nd, the Representative disclosed that they had bought between $1,001 and $15,000 in IDEXX Laboratories stock on April 7th.

Representative April McClain Delaney also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Toro (NYSE:TTC) on 4/29/2025.
• Purchased $1,001 – $15,000 in shares of Bio-Techne (NASDAQ:TECH) on 4/29/2025.
• Sold $1,001 – $15,000 in shares of Dayforce (NYSE:DAY) on 4/28/2025.
• Purchased $1,001 – $15,000 in shares of Markel Group (NYSE:MKL) on 4/24/2025.
• Sold $1,001 – $15,000 in shares of A. O. Smith (NYSE:AOS) on 4/16/2025.
• Sold $1,001 – $15,000 in shares of A. O. Smith (NYSE:AOS) on 4/10/2025.
• Sold $1,001 – $15,000 in shares of Toro (NYSE:TTC) on 4/10/2025.
• Purchased $1,001 – $15,000 in shares of Bio-Techne (NASDAQ:TECH) on 4/9/2025.
• Purchased $1,001 – $15,000 in shares of IDEXX Laboratories (NASDAQ:IDXX) on 4/9/2025.
• Purchased $1,001 – $15,000 in shares of Markel Group (NYSE:MKL) on 4/9/2025.

IDEXX Laboratories Stock Up 0.2 %

IDEXX Laboratories stock traded up $0.81 during mid-day trading on Tuesday, hitting $475.88. The company’s stock had a trading volume of 154,914 shares, compared to its average volume of 642,296. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $548.88. The company has a market cap of $38.56 billion, a PE ratio of 44.60, a price-to-earnings-growth ratio of 3.41 and a beta of 1.52. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The firm’s 50 day moving average is $419.61 and its 200 day moving average is $428.18.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, topping the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The company had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. During the same quarter in the prior year, the business posted $2.71 EPS. IDEXX Laboratories’s quarterly revenue was up 3.6% on a year-over-year basis. On average, analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Hedge Funds Weigh In On IDEXX Laboratories

Hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC increased its holdings in IDEXX Laboratories by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company’s stock valued at $948,279,000 after purchasing an additional 37,734 shares in the last quarter. Bamco Inc. NY boosted its stake in shares of IDEXX Laboratories by 4.3% in the 4th quarter. Bamco Inc. NY now owns 2,005,522 shares of the company’s stock valued at $829,163,000 after purchasing an additional 82,264 shares during the last quarter. Franklin Resources Inc. boosted its stake in IDEXX Laboratories by 2.5% in the third quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company’s stock valued at $675,259,000 after acquiring an additional 34,305 shares during the last quarter. Invesco Ltd. grew its holdings in IDEXX Laboratories by 6.8% during the 4th quarter. Invesco Ltd. now owns 1,160,988 shares of the company’s stock worth $479,999,000 after acquiring an additional 74,324 shares during the period. Finally, Principal Financial Group Inc. lifted its stake in shares of IDEXX Laboratories by 58.3% in the 1st quarter. Principal Financial Group Inc. now owns 1,126,002 shares of the company’s stock valued at $472,865,000 after purchasing an additional 414,802 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently weighed in on IDXX shares. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 12th. Piper Sandler boosted their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research note on Monday, February 10th. Morgan Stanley boosted their target price on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an “overweight” rating in a research report on Monday. Bank of America raised their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Finally, Barclays upped their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $524.75.

Insider Transactions at IDEXX Laboratories

In related news, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares of the company’s stock, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.98% of the stock is owned by corporate insiders.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.